Back to top
more

Acorda Therapeutics, Inc. (ACOR)

(Delayed Data from NSDQ)

$0.94 USD

0.94
7,534,185

-0.02 (-2.48%)

Updated Oct 21, 2020 04:00 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.33%
2Buy17.77%
3Hold9.37%
4Sell4.88%
5Strong Sell1.79%
S&P50010.56%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum D VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 29% (180 out of 254)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Balance Sheet

Research for ACOR

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Acorda Therapeutics Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Assets          
Cash & Equivalents 139 446 307 159 359
Receivables 22 23 81 52 31
Notes Receivable 0 0 0 0 0
Inventories 25 29 38 43 36
Other Current Assets 15 30 15 19 24
Total Current Assets 201 528 442 273 451
Net Property & Equipment 143 61 37 34 40
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 2 7 5
Intangibles 402 711 717 1,023 614
Deposits & Other Assets 30 0 1 6 5
Total Assets 800 1,300 1,198 1,342 1,116
Liabilities & Shareholders Equity 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Notes Payable 1 1 7 6 1
Accounts Payable 26 49 27 27 14
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 39 77 100 105 66
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 13 14 9 10 9
Total Current Liabilities 86 140 144 148 91
Mortgages 0 0 0 0 0
Deferred Taxes/Income 10 7 46 125 54
Convertible Debt 193 319 309 299 297
Long-Term Debt 26 24 26 25 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 152 197 154 81 72
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 489 688 678 678 513
Shareholders Equity 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 979 1,005 969 921 813
Retained Earnings -667 -394 -455 -244 -209
Other Equity -1 3 7 -13 -0
Treasury Stock 1 2 0 0 0
Total Shareholder's Equity 311 612 520 664 603
Total Liabilities & Shareholder's Equity 800 1,300 1,198 1,342 1,116
Total Common Equity 311 612 520 664 603
Shares Outstanding 48.00 47.50 46.70 46.10 43.10
Book Value Per Share 6.48 12.88 11.13 14.41 13.99

Fiscal Year End for Acorda Therapeutics Inc falls in the month of December.

All items in Millions except Per Share data.

9/30/2020 6/30/2020 3/31/2020 12/31/2019 9/30/2019
Assets          
Cash & Equivalents NA 79 96 139 254
Receivables NA 15 15 22 18
Notes Receivable NA 0 0 0 0
Inventories NA 33 26 25 27
Other Current Assets NA 31 32 15 16
Total Current Assets NA 158 168 201 314
Net Property & Equipment NA 142 143 143 131
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 383 390 402 410
Deposits & Other Assets NA 25 30 30 0
Total Assets NA 728 754 800 880
Liabilities & Shareholders Equity 9/30/2020 6/30/2020 3/31/2020 12/31/2019 9/30/2019
Notes Payable NA 67 1 1 1
Accounts Payable NA 15 12 26 27
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 37 37 39 43
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 11 13 13 14
Total Current Liabilities NA 138 71 86 92
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 17 16 10 3
Convertible Debt NA 132 195 193 326
Long-Term Debt NA 26 25 26 25
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 118 152 128
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 437 447 489 599
Shareholders Equity 9/30/2020 6/30/2020 3/31/2020 12/31/2019 9/30/2019
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 983 981 979 1,015
Retained Earnings NA -691 -673 -667 -732
Other Equity NA -1 -1 -1 -1
Treasury Stock NA 1 1 1 1
Total Shareholder's Equity NA 291 307 311 281
Total Liabilities & Shareholder's Equity NA 728 754 800 880
Total Common Equity 0 291 307 311 281
Shares Outstanding 47.90 47.90 47.90 48.00 48.10
Book Value Per Share 0.00 6.07 6.40 6.48 5.85